On May 23, 2018, we published revised versions of our Privacy Policy and User Agreements. Please read these updated terms and take some time to understand them. Your use of our services is subject to these revised terms.
Yes, I Agree.
Stocks To Buy Now


Sugarmade Inc. (SGMD) Focuses on Next-Generation Extraction Tech to Prepare Hemp Sector for Expected Crop Boom

  • SGMD aims to market next-generation hemp machinery and proprietary extraction technologies
  • Hemp extraction and cultivation is a growing business, as the passage of the 2018 Farm Bill continues to result in rising demand
  • SGMD plans to provide both legacy and new technology, including water-based sonification extraction, microwaves and other low-cost techniques and equipment

Sugarmade Inc. (OTCQB: SGMD) plans to offer next-generation equipment and techniques to its customers that process and extract from industrial hemp to help meet what is anticipated to be a peak crop in 2019. To this end, SGMD was recently featured in a CannabisNewsWire analysis article discussing the hemp market’s rising demand for processing power (http://ibn.fm/znmWo).

SGMD’s new initiative includes making available to its customers new technology such as water-based sonification extraction, microwaves and other techniques. These machines could reduce the cost of extraction and help cultivators increase output without significant increases in cost. SGMD is not in the hemp cultivation business itself, but it has a business model centered on supporting cultivators.

The combination of rising demand and the passage of the 2018 Farm Bill, which provides legal relief for hemp cultivators, is driving what is expected to be a record 2019 crop of industrial hemp. SGMD’s initiative is expected to increase the company’s revenue base as it introduces new-generation machinery and proprietary technologies for hemp extraction (http://ibn.fm/FKcnM). Some of the new offerings, which are more efficient and reduce the cost to cultivators seeking to meet the high demand, come from Southern China.

“We plan to not only market several domestic technologies, but also next-generation technologies we plan to implement from Southern China, where hemp cultivation and herbal extraction technologies are well ahead of North America,” SGMD CEO Jimmy Chan stated in a news release. SGMD sees an imbalance between cultivation outputs and extraction capacities within the industry. This record hemp harvest is creating a widespread need for efficient, cost-effective methods of processing within the industry, and SGMD is well-positioned to provide a solution.

“It is clear the 2019 and 2020 hemp cultivation seasons will be massive,” Chan added. “We expect the power balance between the cultivators and extractors to continue to heavily favor extractors, and we are seeing that part of the industry expand massively to be able to handle the significant amount of hemp biomass that will be harvested and will ultimately be processed.”

New Frontier Data projects that hemp sales in the United States will reach $2.6 billion by 2020 (http://ibn.fm/HA69K). Industrial hemp will have a broad impact on the market, the research shows.

Based in Monrovia, California, SGMD is a hydroponics and cultivation supply company that’s committed to supporting the industrial hemp sector. The company is also involved in product and brand marketing for diverse industries, with numerous operations such as packaging and paper goods.

For more information, visit the company’s website at www.Sugarmade.com

NOTE TO INVESTORS: The latest news and updates relating to SGMD are available in the company’s newsroom at http://ibn.fm/SUGAR

From Our Blog

Predictive Oncology Inc. (NASDAQ: POAI) Subsidiary Helomics Leverages Cutting-Edge Tech and Datasets to Improve Cancer Outcomes

May 22, 2020

POAI subsidiary Helomics helps oncologists individualize cancer treatment using patient-derived tumor models to improve outcomes Helomics’ tumor genomic and drug response database is one of the largest in the world with over 150,000 tumors across 137 cancer types Expected CAGR of 10.3% from 2018-2024 for oncology segment of precision medicine industry The relationship between a […]

Rotate your device 90° to view site.